Xenon Pharmaceuticals Q4 EPS $(0.64) Beats $(0.76) Estimate
Portfolio Pulse from Benzinga Newsdesk
Xenon Pharmaceuticals (NASDAQ:XENE) reported Q4 earnings with losses of $(0.64) per share, surpassing the analyst consensus estimate of $(0.76) by 15.79%. However, this represents a 12.28% increase in losses compared to the same period last year.
February 29, 2024 | 9:03 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Xenon Pharmaceuticals reported better-than-expected Q4 losses, but with an increase in losses year-over-year.
While beating EPS estimates typically has a positive impact on stock prices, the increase in losses year-over-year could temper investor enthusiasm. The mixed results suggest a neutral short-term impact on XENE's stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100